AROI-ESTRO GYN Teaching Course

Future research In EMBRACE II, the improved therapeutic window (through increased application and/or OAR dose de-escalation (figure 4.1). In tumours with large residual CTV HR v 716 the potential to improve local control significantly. In limited size CTV HR volumes 717 escalation has minor impact on local control while it has potential to reduce m 718 application of the IC/IS technique in at least 20% of the patients in each institution 719 distribution of ~20% IB, ~50% IIB, ~20% IIIB and ~10% others. If a given patient p 720 limited or extensive disease, the threshold of 20% IC/IS applications must be adapt 721 715

 Dose escalation for advanced disease in HR CTV

 Dose de-escalation for limited and favourable advanced disease (good response,…)

 Testing Dose/Volume constraints and morbidity/QoL  Concomitant ERT-CT and adjuvant chemotherapy for subgroups with high risk of distant metastases

Biomarker investigation (Hypoxia, HPV, EGFR, VEGF..)



Figure 4.1 Principles for dose de-escalation and dose escalation in EMBRACE II. Th 722

GUSTAVE ROUSSY

THÈME DU DIAPORAMA